Vergoeding 2019-2023 voor ATC-subgroep L01EX : Overige proteinekinaseremmers
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021* | 2022* | 2023* | |
|---|---|---|---|---|---|
| L01EX01 Sunitinib | 8.032.955 | 6.895.475 | 6.548.581 | 3.592.892 | 1.386.086 |
| L01EX02 Sorafenib | 2.067.418 | 1.798.610 | 1.301.651 | 1.005.253 | 657.370 |
| L01EX03 Pazopanib | 8.333.623 | 7.260.533 | 5.613.984 | 4.829.414 | 3.701.217 |
| L01EX04 Vandetanib | 900.096 | 889.460 | 1.041.173 | 893.049 | 755.338 |
| L01EX05 Regorafenib | 789.159 | 751.538 | 693.085 | 710.842 | 555.060 |
| L01EX07 Cabozantinib | 10.672.758 | 11.706.782 | 11.620.121 | 8.121.916 | 8.387.910 |
| L01EX08 Lenvatinib | 2.446.142 | 3.059.453 | 3.462.607 | 3.175.048 | 2.645.990 |
| L01EX09 Nintedanib | 285.097 | 176.971 | 163.112 | 173.063 | 77.553 |
| L01EX10 Midostaurine | 6.261.262 | 4.266.839 | 3.661.092 | 3.532.130 | 4.262.644 |
| L01EX12 Larotrectinib | . | . | 10.205 | 269.454 | 397.611 |
| L01EX13 Gilteritinib | . | . | 804.323 | 1.269.234 | 1.727.780 |
| L01EX14 Entrectinib | . | . | . | 58.315 | 63.175 |
| L01EX18 Avapritinib | . | . | 336.389 | 1.997.673 | 764.189 |
| L01EX21 Tepotinib | . | . | . | 9.267 | 834.912 |
| L01EX22 Selpercatinib | . | . | 75.243 | 2.988.389 | 4.406.039 |
| Totaal | 39.788.511 | 36.805.661 | 35.331.567 | 32.625.938 | 30.622.873 |